Showing results (21-30 of 73) with videos related to
Sort By:
Pageof 8
Drug and Alcohol Review|May 13, 2020
Receipt of training about medication for opioid use disorder from pharmaceutical manufacturers: A preliminary study of Florida criminal problem-solving and dependency court staffBarbara Andraka-Christou, Danielle Atkins, Jody Madeira, et al.Substance Use & Misuse|April 7, 2023
Legal Limitations Associated with Microdosing BuprenorphineBarbara Andraka-Christou, Matthew Douglas Evans, Beth Tranen, et al.Health Affairs (Project Hope)|May 1, 2023
Buprenorphine Treatment For Opioid Use Disorder: Comparison Of Insurance Restrictions, 2017-21Barbara Andraka-Christou, Kosali I Simon, W David Bradford, et al.Substance Abuse|September 7, 2023
Will the End of the X-Waiver Expand Access to Buprenorphine Treatment? Achieving the Full Potential of the 2023 Consolidated Appropriations ActBrendan Saloner, Barbara Andraka-Christou, Bradley D Stein, et al.Substance Abuse|April 2, 2021
It will end in tiers: A strategy to include "dabblers" in the buprenorphine workforce after the X-waiverBrendan Saloner, Barbara Andraka Christou, Adam J Gordon, et al.Substance Abuse|July 8, 2021
Criminal problem-solving and civil dependency court policies regarding medications for opioid use disorderBarbara Andraka-Christou, M H Clark, Danielle N Atkins, et al.Substance Use & Misuse|March 20, 2026
Factors Affecting Accessibility of Campus-Based Substance Use Disorder Treatment in a U.S. College SampleFatema Z Ahmed, Barbara Andraka-Christou, Shana Harris, et al.Journal of Substance Abuse Treatment|June 12, 2021
Where did the specialty behavioral health workforce grow between 2011 and 2019? Evidence from census dataThuy Nguyen, Jonathan Cantor, Barbara Andraka-Christou, et al.Journal of Addiction Medicine|October 26, 2019
Comparing Reasons for Starting and Stopping Methadone, Buprenorphine, and Naltrexone Treatment Among a Sample of White Individuals With Opioid Use DisorderOlivia Randall-Kosich, Barbara Andraka-Christou, Rachel Totaram, et al.Addiction Science & Clinical Practice|August 9, 2022
Perceptions of buprenorphine barriers and efficacy among nurse practitioners and physician assistantsBarbara Andraka-Christou, Cory Page, Victoria Schoebel, et al.Pageof 8